Alyftrek Clinical Trials: What FDA Evaluated
FDA approval of Alyftrek drew on two 52-week active-controlled trials in people aged 12 and older and supportive pediatric pharmacokinetic and safety data. The trials found lung-function results noninferior to elexacaftor/tezacaftor/ivacaftor, while the current label contains substantial safety warnings.
Timeline
- 2024-12-20: FDA originally approved Alyftrek.
- 2026-03: FDA labeling expanded eligible CFTR-variant language and added updated safety information.
Alyftrek combines vanzacaftor, tezacaftor and deutivacaftor, three medicines that act on the cystic fibrosis transmembrane conductance regulator protein. FDA originally approved it in December 2024. The current U.S. indication covers adults and children aged 6 years and older who have a clinical diagnosis of cystic fibrosis and at least one CFTR variant that is responsive based on clinical or laboratory data, or produces CFTR protein. Eligibility requires clinical and genetic assessment rather than age alone. [1][2][3]
The principal efficacy evidence came from two randomized, double-blind, active-controlled trials in people aged 12 and older. Everyone first completed a four-week run-in with elexacaftor, tezacaftor and ivacaftor, often abbreviated ELX/TEZ/IVA. Participants were then assigned to once-daily Alyftrek or the active comparator for 52 weeks. Trial 1 included 398 randomized participants and Trial 2 included 573, according to the FDA analysis summarized in the Drug Trials Snapshot. [1][2]
Both trials used change in percent-predicted forced expiratory volume in one second, or ppFEV1, through week 24 as the primary endpoint. This is a standard measure of lung function. Alyftrek met the prespecified test for noninferiority, meaning the results were not worse than the comparator by more than the trial’s allowed margin. Noninferiority does not mean the medicines were identical in every respect or that Alyftrek cured cystic fibrosis. [1][2]
The studies also measured sweat chloride, pulmonary exacerbations and respiratory quality-of-life scores. Alyftrek produced larger average reductions in sweat chloride than ELX/TEZ/IVA in both trials. The current label says the treatment differences through week 24 were minus 8.4 mmol/L in Trial 1 and minus 2.8 mmol/L in Trial 2, while also stating that the clinical relevance of those differences has not been established in interventional trials. That qualification prevents a biomarker improvement from being overstated as a proven additional health benefit. [1][2]
Evidence for children aged 6 to under 12 came from an open-label study plus pharmacokinetic modeling and extrapolation from the older participants’ efficacy results. Seventy-eight children in that age range received Alyftrek in Trial 3. FDA concluded that their drug exposures fell within the range observed in people aged 12 and older, and the label says their overall safety profile was generally similar. This evidence design is different from conducting another large randomized efficacy comparison in younger children. [2]
The safety context is essential. The current label has a boxed warning about drug-induced liver injury and liver failure and requires liver-function testing before treatment and at specified intervals afterward. It also addresses hypersensitivity, intracranial hypertension, neuropsychiatric events, drug interactions and cataract monitoring in pediatric patients. Common adverse reactions in the trials included cough, upper-respiratory symptoms, headache, fatigue, rash and increased liver enzymes. These risks cannot be evaluated from an explainer alone. [2]
Alyftrek is prescription treatment, and this summary is not a recommendation to start, stop or switch CF therapy. Trial participants had specific genotypes and had tolerated the comparator during the run-in, so the results do not answer every individual treatment question. Patients and caregivers should use the current FDA label and discuss genotype, liver monitoring, mental-health symptoms, other medicines and grapefruit exposure with a cystic-fibrosis specialist or pharmacist before making treatment decisions. [1][2]
Sources
- FDA — Drug Trials Snapshot: Alyftrek
- FDA — Alyftrek current prescribing information
- FDA — Novel Drug Approvals for 2024